What it is
Lipo Shredder is the strongest of the lipotropic injections on this site. Lipotropic means fat-moving: these are ready-mixed solutions of vitamins, nutrients, and amino acids injected to shift how the body handles fat.
This is the most aggressive, cutting-oriented formula in the line. It combines fat metabolism support with stimulant-like energy and thermogenesis — the deliberate production of heat as a way of burning off energy, which happens in brown and beige fat cells and in skeletal muscle.
Seven ingredients are named:
L-carnitine carries fatty acids into the mitochondria — the parts of the cell that turn fuel into energy — where they are burned to make ATP, the molecule cells spend.
Methionine is an amino acid that supports liver function and fat metabolism, and feeds production of glutathione, the body's main built-in antioxidant.
Choline exports fat out of the liver, stops fat building up there, and supports thinking and memory.
Inositol improves blood fat levels, improves insulin sensitivity and metabolic regulation, and stabilises mood.
ATP is adenosine triphosphate, the molecule cells actually spend when they use energy.
Albuterol is a stimulant and a bronchodilator — a drug that opens the airways, normally used for asthma. Here it is included to increase alertness and metabolic drive, and for its heat-producing, cutting effect. This is the ingredient that makes this product the aggressive one.
B12 — vitamin B12 — supports energy metabolism, nerve function, and red blood cell production.
The vial comes ready-mixed. Nothing is reconstituted. You draw a dose and inject it into a muscle, an intramuscular injection.
Note: ATP's role here is to boost energy and enhance muscular energy output, as described on the LIPO C+ page.
The stimulant-forward end of the lipotropic line: an albuterol-containing pre-mixed formulation for intramuscular administration, positioned as the most aggressive, cutting-oriented product in the line, combining fat metabolism support with stimulant-like energy and thermogenesis — defined as energy dissipation through specialised heat production in brown and beige adipocytes and skeletal muscle.
Declared constituents and stated roles:
L-carnitine — mitochondrial transport of fatty acids for ATP conversion; direct role in fat utilisation.
Methionine — hepatic function and fat metabolism support; glutathione substrate.
Choline — hepatic fat export; prevention of hepatic fat accumulation; cognitive support.
Inositol — improved lipid profile, insulin sensitivity, metabolic regulation; mood stabilisation.
ATP — as on LIPO C+: primary substrate for cellular energy use and storage, enhancing muscular energy output.
Albuterol — a β2-adrenergic agonist, described as a stimulant and bronchodilator increasing alertness and metabolic drive, with thermogenic and cutting effect. This is the constituent that distinguishes the product, and no quantity is declared for it.
B12 — support of energy metabolism, neurologic function, and erythropoiesis.
No constituent quantities are declared. For an injectable β2-agonist that is the material omission: albuterol's cardiovascular, tremor, and hypokalaemia profile is dose-dependent, and there is nothing to size it against.
What it does
Two things at once, like LIPO C+, but with a stronger stimulant.
The lipotropic half works on fat. Choline moves fat out of the liver; carnitine carries fatty acids into the parts of the cell that burn them; methionine and inositol support the liver and the metabolic regulation around it; B12 supports the energy metabolism that all of it feeds into.
The stimulant half is albuterol. It raises alertness and metabolic drive, and drives thermogenesis — the body producing heat in order to dissipate energy. That is what the cutting effect means: heat production is a way of spending calories.
ATP adds to the energy side.
No benefits list exists for this product beyond the ingredient descriptions and the one-line summary above them.
A lipotropic base with a β2-adrenergic agonist bolted on.
Lipotropic arm: choline-driven hepatic fat export, carnitine-driven mitochondrial long-chain fatty-acid import, methionine supporting transmethylation and glutathione supply, inositol acting on insulin sensitivity and lipid profile, cobalamin supporting the energy metabolism those feed.
Sympathomimetic and thermogenic arm: albuterol, increasing alertness and metabolic drive, with thermogenesis — uncoupled energy dissipation as heat in brown and beige adipose tissue and skeletal muscle — as the stated cutting mechanism. ATP contributes on the energy side.
There are no documented efficacy claims for the finished product beyond the per-ingredient descriptions and its positioning as the line's most aggressive formula.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No dedicated benefits have been documented for this product. What follows comes from its ingredient descriptions and its positioning in the line.Anecdotal
- The most aggressive, cutting-oriented lipotropic formula in the line.Anecdotal
- Combines fat metabolism support with stimulant-like energy.Anecdotal
- Drives thermogenesis — heat production in brown and beige fat cells and in skeletal muscle, which is a way of spending energy.Limited human data
- Increases alertness and metabolic drive, from the albuterol.Anecdotal
- Aids transport of fatty acids into the parts of the cell that burn them, from the L-carnitine.Limited human data
- Supports liver function and fat metabolism, and feeds antioxidant production, from the methionine.Animal or lab only
- Exports fat from the liver, prevents fat accumulating there, and supports thinking, from the choline.Limited human data
- Improves blood fat levels, insulin sensitivity, and metabolic regulation, and stabilises mood, from the inositol.Limited human data
- Supports energy metabolism, nerve function, and red blood cell production, from the B12.Human trials
- No dedicated benefits have been documented; the following derives from the ingredient descriptions and positioning.Anecdotal
- Positioned as the most aggressive, cutting-oriented lipotropic in the line.Anecdotal
- Fat metabolism support combined with stimulant-like energy.Anecdotal
- Thermogenesis — energy dissipation as heat in brown and beige adipocytes and skeletal muscle.Limited human data
- Increased alertness and metabolic drive (albuterol).Anecdotal
- Mitochondrial fatty-acid transport for oxidation (L-carnitine).Limited human data
- Hepatic function and fat metabolism support with glutathione substrate supply (methionine).Animal or lab only
- Hepatic fat export, prevention of hepatic steatosis, cognitive support (choline).Limited human data
- Improved lipid profile, insulin sensitivity, metabolic regulation, mood stabilisation (inositol).Limited human data
- Support of energy metabolism, neurologic function, and erythropoiesis (B12).Human trials
Reconstitution and dosing
Storage first, because it matters most: do not refrigerate this product, before or after use. The LIPO C+ entry explains why — everything in this line is concentrated, and L-carnitine in particular crystallises when it gets cold — and gives a lukewarm-water-bath procedure for dissolving crystals if they form.
The vial comes ready-mixed. Nothing is reconstituted.
Inject into a muscle. Dose in the morning, so it does not disturb your sleep — an instruction that matters more here than on the non-stimulant products in this line. Fasting is not necessary.
A cycle is 8 weeks or more, followed by a break of half the length of the cycle you completed.
The standard dose is 50 to 100 units once a day, 2 to 3 days a week. The advanced dose is 50 to 150 units once a day, 3 to 5 days a week.
About the numbers in the table. The doses are given in syringe units only — "50-100 units" — with no microgram or milligram figure attached, and no ingredient quantities anywhere. The three other lipotropics on this site express the same unit numbers as 500 to 1,000 micrograms, which works out to 1 milligram in every millilitre. The table below uses a placeholder vial of 10 mg in 10 mL so that the draw column reproduces the scheduled unit numbers exactly. Both the milligram figures and the vial size are placeholders for the arithmetic, not facts about the product. The unit numbers are the real instruction here — read the Draw column, not the Dose column.
Storage: do not refrigerate before or after use. The LIPO C+ entry carries the line-wide rationale (high total solute concentration, L-carnitine crystallisation) and the warm-bath recovery procedure.
Pre-mixed solution; no reconstitution.
Intramuscular administration. Morning dosing to avoid sleep disturbance — load-bearing on an albuterol-containing formulation rather than merely advisory. Fasting not necessary.
Cycle: 8 weeks or more, washout half the completed cycle length.
Standard protocol: 50–100 units 1×/day, 2–3 days per week. Advanced protocol: 50–150 units 1×/day, 3–5 days per week. Unit figures identical to Lipo-C, LIPO C+, and Lipo-Mino Mix.
Quantity basis and disclosure. Doses are stated in syringe units alone, with no mass equivalent and no per-ingredient quantities. The three sibling lipotropics pair the identical unit figures with 500–1,000 mcg, implying 10 mcg per insulin unit, i.e. 1 mg/mL. The protocols below carry a derived placeholder of 10 mg in 10 mL on that basis, solely so the draw column reproduces the scheduled unit numbers. Neither the mass figures nor the vial volume are established for this product — the line-wide concentration convention is inferred from the sibling products, and the dose column is therefore shown as units with the millilitre equivalent.
The substantive gap is not the vial size. It is that a formulation containing a β2-agonist is dosed here by syringe graduation with no declared concentration for any constituent, which makes the albuterol exposure per injection unknowable.
Standard protocol
Supplied as a ready-mixed solution — nothing to reconstitute. Doses are given in syringe units only, with no mass figures and no ingredient quantities; the 10 mg in 10 mL shown here is a placeholder taken from the 10 mcg per unit convention the sibling lipotropics use, so the draw column reproduces the scheduled unit numbers. Do not refrigerate before or after use.
1 mg/mL · 10 mcg per unit
Cycle: 8 weeks or more, then a washout of half the cycle length · Frequency: 1×/day, 2–3 days per week; intramuscular; morning; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| Low end of the range | 50 units (0.5 mL of solution) | 50 units | 1×/day, 2–3 days per week |
| Top of the range | 100 units (1 mL of solution) | 100 units | 1×/day, 2–3 days per week |
Advanced protocol
Ready-mixed solution; no reconstitution. Doses are stated in syringe units only; the 10 mg in 10 mL is a placeholder based on the sibling lipotropics' 10 mcg per unit convention. Do not refrigerate.
1 mg/mL · 10 mcg per unit
Cycle: 8 weeks or more, then a washout of half the cycle length · Frequency: 1×/day, 3–5 days per week; intramuscular; morning; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| Low end of the range | 50 units (0.5 mL of solution) | 50 units | 1×/day, 3–5 days per week |
| Top of the range | 150 units (1.5 mL of solution) | 150 units(over 100 units: split across 2 syringes) | 1×/day, 3–5 days per week |
10 mg in 10 mL is 1 mg/mL, or 10 mcg per unit. Draw 50 units (0.5 mL) for 500 mcg.
Who should avoid it
- No contraindications or interactions specific to Lipo Shredder have been documented. Given that the vial contains albuterol, that is a significant gap rather than a reassurance.
- From the LIPO C+ page, the other stimulant-containing product in this line, which does carry a full list — do not use if you are pregnant or breastfeeding.
- From the LIPO C+ page — do not use if you are taking an MAOI, a monoamine oxidase inhibitor, which is an older class of antidepressant.
- From the LIPO C+ page — do not use if you have recently had a cardiovascular event such as a heart attack or a stroke.
- From the LIPO C+ page — do not use if you have uncontrolled high blood pressure or an active heart rhythm disorder.
- From the LIPO C+ page — use only with caution and under direct medical supervision if you have an anxiety or panic disorder, because the stimulant component may make attacks worse or more frequent.
- From the LIPO C+ page — use only with caution and under direct medical supervision if you have an overactive thyroid, because that raises sensitivity to stimulants.
- From the LIPO C+ page — use only with caution and under direct medical supervision if you have liver disease, because lipotropics place a load on the liver's metabolism.
- From the LIPO C+ page — proceed with extreme caution when combining with other stimulants. The list includes caffeine, ephedrine, DMAA and DMHA, albuterol, amphetamine, methamphetamine, methylphenidate, phenelzine, tranylcypromine, pseudoephedrine, and phenylephrine. Note that albuterol is on that list and albuterol is in this vial.
- From the LIPO C+ page — beta blockers and calcium channel blockers may interact. Beta blockers are the direct pharmacological opposite of albuterol, which makes this pairing particularly relevant here.
- From the LIPO C+ page — antiarrhythmic drugs such as amiodarone and flecainide may interact.
- From the LIPO C+ page — drugs the liver has to process, such as statins, some antidepressants, and some anti-seizure medicines, may be metabolised differently under the extra liver load.
- From the LIPO C+ page — SSRIs (selective serotonin reuptake inhibitors, the most commonly prescribed family of antidepressants), antipsychotics, and other drugs acting on the central nervous system may combine with a stimulant to produce unpredictable stimulation or anxiety.
- From the standalone L-Carnitine page, since L-carnitine is a declared ingredient here — the L-Carnitine entry contraindicates cardiovascular disease, heart arrhythmia, uncontrolled high blood pressure, stimulant sensitivity, anxiety or panic disorders, epilepsy, and pregnancy or breastfeeding. It also cautions specifically against stacking L-carnitine with stimulants, which this product does inside a single vial.
- From the standalone L-Carnitine page — there is an increased chance of low blood sugar when combined with diabetes medication such as insulin, metformin, and GLP-1 agonists (glucagon-like peptide-1 receptor agonists, the class that includes semaglutide and tirzepatide).
- From the standalone L-Carnitine page — L-carnitine can work against thyroid hormone activity and may reduce the effectiveness of thyroid replacement medication.
- From the B12 page on this site, since B12 is a declared ingredient here — do not use supplemental B12 if you have chronic kidney problems.
- Note: no quantities are given for any ingredient, and none for albuterol in particular. Albuterol's effects on heart rate, tremor, and blood potassium all depend on dose, and no dose is stated.
- Note: injected albuterol is not a routine route for that drug. What that changes has not been established.
- No contraindications, cautions, or interactions specific to this product have been documented — a material omission for an albuterol-containing injectable.
- From the LIPO C+ page, the line's stimulant-containing sibling and its only full interaction reference: pregnancy and lactation — contraindicated.
- From the LIPO C+ page: concurrent MAOI therapy — contraindicated.
- From the LIPO C+ page: recent cardiovascular event (myocardial infarction, stroke) — contraindicated.
- From the LIPO C+ page: uncontrolled hypertension or active cardiac arrhythmia — contraindicated.
- From the LIPO C+ page: anxiety or panic disorder — direct medical supervision only; stimulant component may increase incident severity and frequency.
- From the LIPO C+ page: hyperthyroidism — direct medical supervision only; increased stimulant sensitivity.
- From the LIPO C+ page: hepatic disease — direct medical supervision only, given lipotropic metabolic burden.
- From the LIPO C+ page: extreme caution combining with caffeine, ephedrine, DMAA/DMHA, albuterol, amphetamine, methamphetamine, methylphenidate, phenelzine, tranylcypromine, pseudoephedrine, or phenylephrine. Albuterol appears on that list and is a constituent here, which makes co-administration of these two products self-contradictory and makes any additional β-agonist exposure additive.
- From the LIPO C+ page: beta blockers and calcium channel blockers may exaggerate hypotension or bradycardia. The beta blocker entry carries extra weight here — non-selective β-blockade directly antagonises albuterol and, in the reverse direction, β-agonist exposure can destabilise rate control.
- From the LIPO C+ page: antiarrhythmics — amiodarone, flecainide.
- From the LIPO C+ page: hepatically metabolised drugs — statins, certain antidepressants, certain anticonvulsants — under additive methylation and hepatic load.
- From the LIPO C+ page: stimulant plus CNS-active agents (SSRIs, antipsychotics) may produce unpredictable stimulation or anxiety.
- From the standalone L-Carnitine page, L-carnitine being declared here: contraindicated in cardiovascular disease, arrhythmia, uncontrolled hypertension, stimulant sensitivity, anxiety or panic disorder, epilepsy, and pregnancy or lactation. The L-Carnitine entry also cautions that combining carnitine with other fat-metabolism agents or stimulants may cause overstimulation, tachycardia, or jitteriness — which describes this formulation's own design.
- From the standalone L-Carnitine page: increased hypoglycaemia risk with insulin, metformin, and GLP-1 agonists.
- From the standalone L-Carnitine page: antagonism of thyroid hormone activity, potentially reducing the effectiveness of thyroid replacement. Set against the hyperthyroidism caution above, the thyroid picture here runs in both directions.
- From the B12 page on this site, B12 being declared here: supplemental B12 is contraindicated in chronic renal disease.
- Note: no constituent quantities are declared. Albuterol's chronotropic, tremorigenic, and hypokalaemic effects are dose-dependent, and nothing permits them to be sized.
- Note: parenteral albuterol is not a routine administration route for that agent, and the pharmacokinetic consequence of bypassing inhaled or oral delivery has not been addressed.
- Note: β2-agonists lower serum potassium. No electrolyte monitoring guidance exists, and the omission matters more on a repeated-dose schedule than on a single one.
Side effects
- No side effects specific to Lipo Shredder have been documented. The entries below come from related entries on this site.
- From the LIPO C+ page, the line's other stimulant product — a reaction where you inject, meaning redness, swelling, or itching.
- From the LIPO C+ page — a faster heart rate.
- From the LIPO C+ page — jitteriness.
- From the LIPO C+ page — anxiety.
- From the LIPO C+ page — irritability.
- From the LIPO C+ page — sweating.
- From the LIPO C+ page — raised blood pressure.
- From the LIPO C+ page — insomnia, or smaller disturbances to sleep.
- From the LIPO C+ page — heart palpitations.
- From the LIPO C+ page — a change in the smell of your body odour.
- From the Lipo-C page, which shares the methionine, choline, and carnitine base — nausea, urinary problems, fatigue, constipation, numbness in the feet or hands, excessive sweating or salivation, and fatigue immediately after the injection.
- From the Lipo-C page — kidney damage if you do not stay properly hydrated.
- From the B12 page, since B12 is in this vial — too much B12 in the system can cause headaches, nausea, vomiting, diarrhoea, and skin problems including itching, rashes, and acne. More seriously, it can cause heart problems, blood clots, and neurological symptoms including tingling, numbness, confusion, and disorientation.
- From the standalone L-Carnitine page — nausea, vomiting, abdominal cramping, diarrhoea, a fishy body odour at higher doses, restlessness, insomnia, headache, and low blood sugar particularly in diabetics.
- Note: none of the well-known effects of albuterol have been documented for this product — no tremor, no racing heart, no anxiety attributable to the drug itself, no low potassium. The ingredient is described only in terms of what it is there to do.
- No adverse effects specific to this product have been documented. Every entry below is drawn from a related entry.
- From the LIPO C+ page, the line's other stimulant-containing product: injection site reaction (erythema, swelling, pruritus), tachycardia, jitteriness, anxiety, irritability, sweating, elevated blood pressure, insomnia or lesser sleep disturbance, palpitations, altered body odour.
- From the LIPO C+ page: the two adverse-interaction clusters defined there apply to any stimulant lipotropic — tachycardia with palpitations and elevated blood pressure (cardiovascular), and anxiety or agitation with insomnia and headache (CNS).
- From the Lipo-C page, which shares the methionine/choline/carnitine base: nausea, urinary disturbance, fatigue, constipation, peripheral paraesthesia, excessive sweating or salivation, immediate post-injection fatigue.
- From the Lipo-C page: renal damage in the absence of adequate hydration.
- From the B12 page, cobalamin being declared here: excess accumulation presenting as headache, nausea, vomiting, diarrhoea, and cutaneous effects (pruritus, rash, acne); more seriously as cardiac events, thrombosis, and neurological symptoms including paraesthesia, numbness, confusion, and disorientation.
- From the standalone L-Carnitine page: nausea, vomiting, abdominal cramping, diarrhoea, trimethylamine-type fishy body odour at higher doses, restlessness, insomnia, headache, and hypoglycaemia particularly in diabetics and those on insulin or glucose-lowering drugs. The L-Carnitine entry also notes L-carnitine may increase seizure frequency in epileptics.
- Note: no albuterol-specific adverse effect has been documented — no tremor, no reflex tachycardia, no hypokalaemia, no paradoxical bronchospasm. The constituent is described for its intended effect only.
- Note: with albuterol's class effect on serum potassium, and with no quantity declared, there is no basis for judging whether electrolyte monitoring is warranted on a 3–5 day-per-week schedule.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Not a stack — the step down, and the page to read first. LIPO C+ is somewhat less potent than this product, and its entry is the only one in this line that sets out the interactions and cautions that come with a stimulant. Do not run the two together: both contain stimulants, and combining stimulants is warned against.
The line's interaction reference and its de-escalation option — Eria jarensis in place of albuterol, explicitly positioned as less potent. Co-administration is contraindicated by the LIPO C+ stimulant list, which names albuterol.
The non-stimulant product in this line. Same schedule, same lipotropic base, no albuterol and no Eria jarensis.
The stimulant-free base formulation on an identical schedule; the appropriate substitution where the sympathomimetic arm is the problem rather than the lipotropic one.
A declared ingredient of this vial, also sold on its own. Its entry carries additional warnings, including about epilepsy, thyroid medication, and diabetes medication.
Declared constituent at an undisclosed dose. The standalone entry's contraindication set and its explicit caution against combining carnitine with stimulants apply directly to a formulation that pairs the two by design.
Also a declared ingredient here. Worth reading before adding more B12 on top, and for its kidney-disease warning.
Declared constituent at an undisclosed dose. The standalone entry carries the chronic renal disease contraindication and the excess-accumulation profile, and is the reference point before any additional cobalamin is stacked on.
Dosing figures have been reviewed and units are recomputed from the stated protocol.